Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series by Sousa, DC et al.
   1 
Title 
Anterior ischemic optic neuropathy and hematological malignancy: a systematic 
review of case-reports and case-series 
 
Authors 
David Cordeiro Sousa MD1; Filipe Brogueira Rodrigues MD1,2, Gonçalo Duarte 
MD1,2, Fátima Campos MD MSc3, Filomena Pinto MD3; Vaz-Carneiro A MD PhD4 
 
Affiliations 
1 Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, 
University of Lisbon, Portugal. 
2 Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. 
3 Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar de 
Lisboa Norte, Portugal. 
4 Center for Evidence-Based Medicine, Faculty of Medicine, University of Lisbon, 
Portugal. 
 
Contact information 
António Vaz-Carneiro 
  2 
Center for Evidence-Based Medicine,  
Faculty of Medicine, University of Lisbon, Portugal. 
Av. Prof. Egas Moniz  
1649-035 Lisboa 
Portugal 
E-mail: avc@fm.ul.pt 
 
Contact 
David Sousa, davidscsousa@gmail.com 
Filipe Rodrigues, filipebrodrigues@gmail.com  
Gonçalo Duarte, gnsilvaduarte@gmail.com  
Filomena Pinto, filomenatpinto@sapo.pt 
Fátima Campos, fatimcampos@gmail.com 
António Vaz-Carneiro, avc@fm.ul.pt 
 
Word Count: 2619 
  
  3 
ABSTRACT 
Objectives. Demographic and clinical characteristics associated with non-arteritic 
anterior ischemic optic neuropathy (NAION) are well described. Patients with 
hematological neoplasms may share some of these characteristics and it may be 
clinically useful to better understand this set of patients. Our objective is to 
systematically review the characteristics of patients with both hematological 
malignancies and NAION. 
Design. Systematic review. 
Participants: Patients with NAION diagnosis related in time to a haematological 
neoplasm.  
Methods. Data sources: MEDLINE, Web of Science, LILACS, SciELO and 
OpenGrey. Study eligibility criteria: Case-reports and case-series. 
Results. We found 261 records, with 15 studies included plus our case-report. A 
total of 19 patients (8 female) with mean age of 54,6 years (range 12-87) were 
analysed: 37% (7) non-Hodgkin lymphoma; 26% (5) myeloproliferative neoplasms; 
21% (4) myelodysplasia; 16% (3) leukemias. Limitations: Verification bias, inability to 
test statistical association between NAION and hematological neoplasms, small 
number of cases and confounding factors related to medical history and specific 
interventions in each case limited the robustness of our conclusions.   
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Conclusions. Our results identified the characteristics of patients with NAION and 
hematological neoplasms related in time. Further observational studies may 
enlighten the importance of looking for evidence of an occult neoplastic disorder in 
patients presenting with NAION. A prompt diagnosis would be of invaluable 
significance for the best management, in terms of follow-up and therapeutics. 
Funding for the systematic review: none 
Systematic review registration number: CRD42015019360 
 
Keywords: Anterior ischemic optic neuropathy, hematologic neoplasm, systematic 
review, case report.  
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1. INTRODUCTION  
1.1. Rationale 
Ischemic optic neuropathy (ION) is the most common acute optic neuropathy in 
patients over the age of 501. The ischemic injury may be localized to the anterior part 
of the optic nerve – anterior ischemic optic neuropathy (AION) or to its retrobulbar 
portion – posterior ischemic optic neuropathy. There are two etiologic forms of AION: 
arteritic and non-arteritic. The first is related to giant cell arteritis and represents 5-
10% of the cases and the latter accounts for the remaining 90-95% of cases1, 4, 5. 
Although the exact mechanism is not completely understood, the proposed etiology 
of non-arteritic AION (NAION) is ischemia of the optic nerve head in patients with 
cardiovascular risk factors1, 2, 3. 
Cross-sectional studies have estimated the prevalence of systemic diseases that 
might predispose to NAION 6, 7N and hematological malignancies8, 9 results of 
previously published case-reports and case-series in order to better understand the 
specific characteristics - including diagnostic, management and prognostic features -  
of patients who shared the diagnosis of NAION and hematologic malignancy.  
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1.2. Objectives 
To report the case of a patient with a hematological malignancy and NAION, and to 
conduct a systematic review of previously published cases of hematological 
malignancies related in time with NAION, discussing its potential implications. 
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2. METHODS 
Our systematic review protocol was registered with PROSPERO  
(CRD42015019360) and written accordingly to PRISMA-P statement10. 
 
2.1. Case report 
The case report was set up after patient consent as defined by the ethical guidelines 
at Centro Hospitalar Lisboa Norte, Portugal. Written informed consent was obtained. 
Data were collected retrospectively after appraisal of medical records. For the 
purposes of case reporting we followed CARE guidelines11. 
 
2.2. Systematic review 
The systematic review was conducted in line with PRISMA12 statement. Statistical 
data respected SAMPL guidelines13. 
 
2.2.1. Eligibility Criteria  
Case reports and series reporting original data of i) adult and pediatric cases of ii) 
NAION related in time to a haematological neoplasm were accepted. Other study 
types were excluded. Only published data were accepted. No study was dismissed 
due to lack of quality, language or time restrictions. 
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2.2.2. Definitions  
NAION was defined as an ischemic neuropathy of the optic nerve, a clinical entity 
characterized by sudden and permanent loss of vision, optic disc edema or, 
alternatively, an atrophic appearance of the optic nerve head 1-2 months after the 
initial loss of vision14, 15.  
We used the WHO definitions for all the haematological conditions described16.  
For data extraction and analysis the above-mentioned definitions were followed. 
Nevertheless, for the study selection process definitions akin to these were allowed. 
 
2.2.3. Information Sources  
We searched MEDLINE, Web of Science, SciELO and LILACS. Grey literature was 
searched via OpenGrey. The last search occurred on April 2015. Reference lists of 
relevant studies were also scanned.  
 
2.3.4. Search Strategy  
A highly sensitive filter was used to retrieve observational studies 17.  
The search strategy was restricted to humans participants.  
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The developed search strategy for all databases combined the terms (anterior 
ischemic optic neuropathy) with (hematologic neoplasms OR lymphoproliferative 
disorders OR leukemia OR lymphoma OR plasma cell neoplasms OR 
myelodysplasic-myeloproliferative diseases OR myelodysplastic syndromes OR 
myeloproliferative disorders) (supplementary file 1). 
 
2.3.5. Study Records 
2.3.5.1. Selection Process 
GD and DS independently screened the titles and abstracts yielded by the search 
against the inclusion criteria. They obtained full reports for all titles that appeared to 
meet the inclusion criteria or in cases of any uncertainty. GD and DS then 
independently screened the full text reports and decided whether these meet the 
inclusion criteria. Additional information was sought from study authors where 
necessary to resolve questions about eligibility. Disagreements were resolved 
through discussion, with FR serving as the final arbitrator. None of the review 
authors were blind to the journal titles or to the study authors or institutions.  
The Cohen’s kappa (κ) coefficient was used to calculate the inter-observer bias in 
accordance to Higgins and Deeks, 201118. 
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2.3.5.2. Data Collection Process 
GD and DS extracted data in duplicate from the included studies to a pre-piloted 
electronic form. In case of irresolvable disagreements, these were adjudicated by 
FR.  
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RESULTS 
Case Report 
A 76-year-old Caucasian man with a myelodysplastic syndrome presented to the 
emergency department with a two-week history of progressive fatigue and recent 
blurred vision in the right eye. Clinical examination was unremarkable. Blood 
analysis revealed leukopenia, thrombocytopenia and myeloid blast forms (>20%). 
Further investigation revealed hepatomegaly and splenomegaly. The diagnosis of 
secondary acute myeloid leukemia (AML) was made. The patient was proposed for a 
FLAG chemotherapy regimen followed by hydroxyurea. Ophthalmological evaluation 
in the emergency department revealed sectorial edema of the optic nerve head and 
the patient was referred for investigation. On observation, best-corrected visual 
acuity (VA) was 20/80 OD and 20/24 OS. A right eye relative pupillary afferent defect 
was present. On fundus examination, a pale right optic disc was observed (figure 
1). Left eye was normal. Right eye macular optic coherence tomography (OCT) 
showed atrophy of the internal retinal layers.  Peripapillary nerve fiber layer OCT 
exposed atrophy in the inferior quadrants (figure 2). Visual fields revealed a 
unilateral superior arcuate defect in the affected eye, being normal in the fellow eye. 
A thorough investigation excluded inflammatory and infectious etiologies. The 
diagnosis of an anterior ischemic optic neuropathy was made and the patient was 
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proposed for risk factor control and regular ophthalmologic follow-up. At 6 and 12 
months follow-up, the AML was stable on hydroxyurea. Clinical findings, VA and 
OCT remained unchanged.  
The diagnosis of an anterior ischemic neuropathy related in time with the acute 
myeloid leukemia compelled us to systematically review this topic.  
 
Study Selection  
The electronic search provided 261 citations. One further citation was added after 
hand search. After deduplication 233 citations remained - 206 of these were 
excluded by screening the abstracts for the inclusion criteria. The degree of 
concordance between screeners was moderate: k=0.5442 (95% CI: 0.418–0.671). 
Two studies were excluded because full texts were not available, after contacting the 
authors19, 20. The 27 remaining citations were analyzed in their full text form for 
additional information. Of these 12 were excluded. A total of 15 studies (18 patients) 
- 13 case reports and 2 case series - met the inclusion criteria21-35 (figure 1). We also 
included our current case report for the final analysis, yielding a total of 19 patients.  
 
Study Characteristics 
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All included studies were in English. The countries of origin for the 19 individuals 
identified for the final analysis were:  4 (21%) from the United States of America; 3 
(16%) from each of Greece, Switzerland and the United Kingdom; and 1 (5%) from 
each of Canada, India, Morocco, Oman, Portugal and Taiwan. The years of 
publication varied from 1990 to 2013. Table 1 summarizes study and demographic 
characteristics. 
 
Demographic Characteristics 
The included studies yielded 19 patients, 8 (42%) of whom were female. The mean 
age was 54.6 years (range:12-87).  
 
Hematologic neoplasm data 
Of the 19 patients, 7 (37%) had a non-Hodgkin lymphoma, 5 (26%) had a 
myeloproliferative neoplasm, 4 (21%) had a myelodysplastic syndrome and 3 (16%) 
had a form of leukemia. One of the patients classified as having a MDS later 
converted into an AML before presenting with NAION. Of the total, 8 (42%) patients 
had NAION diagnosed before the diagnoses of their hematologic neoplasms. Ten 
(53%) patients had the hematologic neoplasm diagnosed before the NAION and in 
one patient this information was no specified. In the cases where the hematologic 
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neoplasm was diagnosed before the NAION, the time elapsed before NAION ranged 
from 60 days to 7 years. Nine (47%) patients died within a year of NAION diagnosis, 
while 7 (37%) underwent remission/stabilization. Of the patients firstly diagnosed 
with NAION, the diagnosis of hematologic malignancy ranged from 10 days to 4 
months afterwards. Outcome data were not provided for 3 (16%) patients. 
 
Ophthalmologic data 
The presenting ophthalmologic symptom was acute loss of vision in all cases. The 
mean VA at presentation was 20/120. During follow-up, VA improved in 6 (32%) 
patients, worsened in 4 (21%) and remained stable in 5 (26%).  Four (21%) patients 
were lost to follow-up. Last documented VA was 20/60. An afferent pupillary defect 
was found in 15 (79%) patients and was not described in the remaining 4 (21%). Of 
all patients, 9 (47%) had an initial simultaneous bilateral presentation, and 4 (21%) 
had sequential bilateral NAION diagnosis. Optic disc edema was present in 17 (90%) 
cases and absent in 1 (5%), being unmentioned in one. A pale disc appearance was 
present in 12 (63%) cases and not defined in 6 (32%). A crowded disc (or disc-at-risk 
appearance) was described in only one patient. Furthermore, 8 (42%) patients had 
disc haemorrhages. Fundus fluorescein angiography was abnormal in 6 (32%) 
cases, demonstrating delayed arterial filling and confirming the optic disc edema. It 
  15 
was not reported in the remaining 13 (68%) patients. Visual field examination 
revealed a generalized depression in 7 (37%) cases, an arcuate scotoma and an 
altitudinal defect in 2 (10%) cases each, and unspecific findings in the remaining 2 
(10%). Visual field examination was not mentioned in 7 (37%) reports. C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) were both in the normal 
range values in 7 (37%) patients, were both elevated in 2 (10%) and were not 
reported in 7 (37%) cases. ERS was isolatedly high in 2 (10%) patients and CRP in 1 
(5%). Table 2 summarizes clinical data. 
 
Medical Interventions 
Ten (52%) patients had a history of corticosteroid use before or at the time of NAION 
diagnosis. Ten (52%) patients had a history of antineoplastic agent use before or at 
the time of NAION diagnosis. Five (26%) patients had a history of using a form of 
immunosuppressive therapy before or at the time of NAION diagnosis. No other 
medical intervention was present consistently across the included studies.  
 
Other systemic diseases 
Some accepted risk factors for NAION development include systemic microvascular 
risk factors (e.g. systemic hypertesion and diabetes).1 In thirteen (68%) patients, 
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there was no concurrent systemic medical illnesses assumed as potential risk factors 
for NAION. Table 2 summarizes the systemic diseases of remaining patients, 
besides the hematologic neoplasm.  
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DISCUSSION 
Summary of evidence  
Although based on an underreported sample of the number of patients with either 
condition, our results describe the demographic and clinical characteristics of a 
cluster of patients who share the diagnosis of both a NAION and a hematologic 
neoplasm. For all the 19 patients included and described in this systematic review 
there was a clear relation in time between these entities. 
 
Which comes first: optic neuropathy or the hematologic neoplasm? 
Intriguingly, eight (42%) patients had NAION diagnosed before the diagnoses of their 
hematologic neoplasm. As we mentioned before, the time elapsed from the NAION 
to the hematologic malignancy diagnosis ranged from 10 days to 4 months. 
However, this may be inaccurate in the sense that the NAION could be a 
manifestation of a still non-diagnosed hematologic neoplasm. This finding raises the 
hypothesis of the potential for earlier diagnosis of hematological disease following an 
optic nerve ischemic event. 
It is also important to discuss the causal mechanism involved in such cases where 
there is an association of these two diseases. We did not find any intervention known 
to predispose consistently to NAION across cases and merely 10 (52%) of patients 
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were taking some form of antineoplastic agent. Pathophysiologically, malignancy is 
well known as a risk factor for prothrombotic states. An increased susceptibility to 
thromboembolic occlusion of ocular arteries is a possible explanation and its 
implications are discussed below. In specific hematologic neoplasms, with excess 
cells in circulation and leukostasis may play the main role for the ischemic event. 
 
Is NAION and hematologic neoplasms different to isolated NAION? 
In addition, to better understand the mechanisms of disease, we might be able to 
find clinical differences in NAION related to different etiologies. Around 95% of 
NAION have presumed atherosclerotic etiologies1. From the 19 patients described, it 
was not possible to find neither a difference between different neoplasms nor 
between different medical interventions. Frequencies among gender and age were 
also not different from other NAION etiologies. As detailed in table 2, thirteen (68%) 
patients with NAION did not present typical systemic risk factors for development of 
this clinical entity (i.e. hypertension, diabetes or other). Also, only one patient was 
described to have a crowded optic disc. Last but not least, simultaneous or 
sequential bilateral NAION was identified in 9 (47%) and 4 (21%) patients, 
respectively. This trend for common bilateral disease is not common in published 
literature.36 In this regard, one must have in mind that a bilateral NAION without 
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typical risk factors may be a presenting manifestation a hematologic neoplasm. 
However, our conclusions are inevitably limited due to the limited number of patients 
identified in this study design. Further works, including specific diagnostic tests such 
as ocular coherence tomography and other imaging modalities could help us to 
enhance differences and eventually suggest new mechanisms of disease. 
In future studies, it would also be relevant to know if different hematological 
conditions are more prone to ocular prothrombotic phenomena. 
 
Limitations of methodology 
Firstly, the very fact that this study was based on case reports and case series is a 
source of possible bias, namely verification bias.   
The relatively small number of gathered cases inevitably limits our conclusions.  
As a methodological definition, systematic reviews cannot establish a statistical 
association, in this case between NAION and hematological neoplasms.  
Also, confounding factors related to medical history and specific interventions in 
each of the cases may have contributed differently for the ischemic events. 
Chemotherapy regimens, radiotherapy sessions and age itself need to be controlled 
and taken into account in different studies with a distinct goal. 
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Lastly, it is not possible to make conclusions about the influence of the hematologic 
disease in the ophthalmologic prognosis (see table 3). Many more variables should 
be included and a different group of comparisons made. Again, further studies can 
address this relevant question. 
 
Implications for clinical practice and clinical research 
Infrequent presentation of a frequent group of diseases 
The diagnosis of NAION related in time in hematologic neoplasms may be 
considered a rare presentation of a frequent group of diseases - hematologic 
neoplasms. As summarized in table 3, 8 (42%) patients presented with NAION 
before the hematologic neoplasm in opposition to 10 (53%) patients in whom the 
neoplasm was diagnosed first. This review identifies the clinical characteristics of 
patients with NAION and hematological neoplasms related in time. Further 
observational studies may enlighten the importance of looking for evidence of an 
occult neoplastic disorder in patients presenting with NAION. Or vice-versa, would it 
be important to pay attention and screen for painless loss of vision in patients with 
hematologic neoplasms? Contemporary medical care in developed countries invests 
a lot in diagnostic testing, to detect disease as early as possible and, hence, 
increasing chances of treating it effectively. Still, clinical examination and medical 
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history are more accessible, many times simpler and assuredly cheaper. Using the 
best scientific and clinical knowledge, we should be alert to promptly diagnose or 
prevent expected diseases or complications.  
 
Unmet needs 
Stated already as a limitation of systematic reviews, larger observational studies are 
needed to assess whether or not there is an association between these diseases. 
For this purpose, a case-control study is likely the optimal study design to investigate 
this question. Additionally, it is also important to investigate if the hematologic 
disease could be related with the ophthalmologic prognosis. This could be of 
invaluable significance for better management, in terms of follow-up and 
therapeutics. 
 
CONCLUSION 
Taking all topics into consideration, our review suggests the need to address the 
infrequently explored and described patients who share hematological neoplasms 
and ophthalmological vasculopathies such as NAION. A potential change in clinical 
practice, namely in disease screening and management, would be important in 
optimizing the care provided for these patients, from diagnosis to treatment. 
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Figure Legends 
Figure 1 - Colour fundus photography. Optic disc atrophy - more marked in the 
temporal side. 
Figure 2 - Ocular coherence tomography of peripapillary retinal nerve 
fiber layer (Panels A-D). Inner layers thinning and atrophy predominantly in the 
inferior quadrants, compatible with the superior visual field defect. 
Figure 3 - Flow diagram of the systematic review.  
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Tables legends 
Table 1. Demographic patient characteristics. 
Table 2. Clinical characteristics. 
Table 3.  Summary.  
 
